A comprehensive overview of recent advances in nanobiosensor technologies for detecting lung cancer-associated ncRNAs is provided, highlighting their substantial diagnostic potential while critically addressing the technical bottlenecks, reproducibility challenges, and regulatory hurdles that must be overcome for their successful clinical translation.
Abstract
Lung cancer remains one of the most prevalent and lethal malignancies worldwide, resulting in approximately 1.5 million deaths annually. Currently, more than 75% of cases are diagnosed at an advanced stage due to the lack of effective early detection methods. Although several conventional diagnostic techniques are available, many exhibits limited sensitivity for early-stage detection and are often associated with high costs and invasiveness. Therefore, there is an urgent need for more accurate, cost-effective, and rapid approaches for early screening. Numerous lung cancer-associated non-coding RNAs (ncRNAs) have been extensively investigated as promising biomarkers for diagnosis, prognosis, and therapeutic monitoring. To leverage these biomarkers, various nanomaterial-enhanced biosensors—utilizing electrochemical, optical, and electromechanical platforms—have been developed for the rapid and selective detection of ncRNAs. This review provides a comprehensive overview of recent advances in nanobiosensor technologies for detecting lung cancer-associated ncRNAs, highlighting their substantial diagnostic potential while critically addressing the technical bottlenecks, reproducibility challenges, and regulatory hurdles that must be overcome for their successful clinical translation.
This review summarizes relevant biosensor types, including electrochemical, optical, mass-sensitive, microfluidic, nano-biosensors (recently developed), and hydrogel-based systems with discussion of their underlying analytical principles and performance for clinically important cancer biomarkers.
The present review focuses on the significance of ncRNAs as diagnostic markers for PCa and summarizes recent progress in biosensing technologies, emphasizing electrochemical methods designed to identify ncRNAs associated with this cancer.
Zahra Oushyani Roudsari, Asma Vafadar, F. Altalbawy et al.· Clinica chimica acta; intern...· 0 citations
This review provides a focused overview of recent advancements in ncRNA-targeted biosensing interfaces, evaluating their operational frameworks and challenges regarding breast cancer diagnosis and monitoring.
Phage-based biosensors have great potential for use in the early identification of disease, which would provide viable alternatives to liquid biopsy as well as point-of-care testing techniques for early identification of cancers.
Qamar Abuhassan, G. Oriquat, Subbulakshmi Ganesan et al.· Clinica chimica acta; intern...· 0 citations
Although pre-analytical limitations remain to be fully characterized, integrating CRISPR into the diagnostic workflow may contribute to a rapid, cost-effective, and highly specific framework for the early detection of PDAC.
M. A. Rocco, Milda Kirvaitytė, Giulia Lencioni et al.· Cancer Letters· 0 citations
Non-small-cell lung cancer (NSCLC) diagnosis is challenged owing to the need for reliable, non-invasive biomarkers. Circulating cell-free microRNAs (ccf-miRNAs) are promising candidates, but their low levels and short sequences in blood complicate detection. In this study, a novel nano-hybrid fluorescent array was deve...
P. K. Mishra, R. Shandilya, Arpit Bhargava et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.